enmd 2076
Small moleculeexperimental
Clinical trial activity
17 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
10
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 1998 (NCT00003755)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 2
- Endometrial Neoplasms · Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Hamartoma · Phase 2
- Hematologic Neoplasms · Phase 1
- Liver Neoplasms · Phase 2
- Multiple Myeloma · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Primary Myelofibrosis · Phase 1
- Sarcoma · Phase 2
- Triple Negative Breast Neoplasms · Phase 2
Mechanism of action
Platelet-derived growth factor receptor inhibitor
- Fibroblast growth factor receptorINHIBITOR
Fibroblast growth factor receptor inhibitor
- SRCINHIBITOR
SRC inhibitor
- Tyrosine-protein kinase Fyn (FYN) ↗
- Proto-oncogene tyrosine-protein kinase Src (SRC) ↗
- Tyrosine-protein kinase Lck (LCK) ↗
- Tyrosine-protein kinase Yes (YES1) ↗
- Tyrosine-protein kinase Blk (BLK) ↗
- Tyrosine-protein kinase HCK (HCK) ↗
- Tyrosine-protein kinase Lyn (LYN) ↗
- Tyrosine-protein kinase FRK (FRK) ↗
- Tyrosine-protein kinase Fgr (FGR) ↗
- Tyrosine-protein kinase Srms (SRMS) ↗
FLT3 inhibitor
Tartrate salt of ENMD-981693
CSF1R inhibitor
Tartrate salt of ENMD-981693
- Stem cell growth factor receptorINHIBITOR
KIT inhibitor
Tartrate salt of ENMD-981693
KDR inhibitor
- Fibroblast growth factor receptor 3INHIBITOR
FGFR3 inhibitor
Tartrate salt of ENMD-981693
AURKA inhibitor
AURKB inhibitor
Tartrate salt of ENMD-981693
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1- Mol. weight
- 375.48 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL52885 ↗
- ChEMBLCHEMBL482968 ↗
Also known as
- enmd2076
- enmd 2076
- enmd-2076
- enmd-2076
- enmd-2076
- enmd-2076
- enmd-981693
- enmd-981693
- mkc-1
- mkc-1
- mkc-1
- r-440
- r-440
- ro-317453
- ro-317453
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02234986 | Phase 2 | Oct 1, 2015 | CASI Pharmaceuticals, Inc., Cornell University |
| NCT01914510 | Phase 2 | Sep 1, 2013 | University of Toronto |
| NCT01719744 | Phase 2 | Jan 1, 2013 | University of Toronto |
| NCT01639248 | Phase 2 | Jul 1, 2012 | CASI Pharmaceuticals, Inc., Indiana University, University of Colorado, Denver |
| NCT01104675 | Phase 2 | Apr 1, 2010 | CASI Pharmaceuticals, Inc. |
| NCT00904787 | Phase 1 | Apr 1, 2009 | CASI Pharmaceuticals, Inc. |
| NCT00806065 | Phase 1 | Dec 1, 2008 | CASI Pharmaceuticals, Inc. |
| NCT00658671 | Phase 1 | Apr 1, 2008 | CASI Pharmaceuticals, Inc. |
| NCT00656461 | Phase 1 | Mar 1, 2008 | CASI Pharmaceuticals, Inc., University of Wisconsin |
| NCT00607607 | Phase 2 | Jan 1, 2008 | CASI Pharmaceuticals, Inc., University of Toronto |
| NCT00568646 | Phase 2 | Nov 1, 2007 | CASI Pharmaceuticals, Inc., Harvard University |
| NCT00506402 | Phase 1 | Nov 1, 2006 | CASI Pharmaceuticals, Inc., University of Toronto |
| NCT00408226 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2006 | CASI Pharmaceuticals, Inc., Indiana University |
| NCT00306631 | Phase 2 | Jan 1, 2006 | CASI Pharmaceuticals, Inc. |
| NCT00016250 | Phase 2 | Dec 1, 2000 | Cornell University, National Cancer Institute (NCI) |
| NCT00014365 | Phase 1 | Oct 1, 2000 | Cornell University, National Cancer Institute (NCI) |
| NCT00003755 | Phase 1 | Oct 1, 1998 | Cornell University, National Cancer Institute (NCI) |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CASI Pharmaceuticals, Inc. | For profit | 12 | 12 | 2 | 2006 |
| Cornell University | Academic/Hospital | 4 | 3 | 2 | 1998 |
| University of Toronto | Academic/Hospital | 4 | 2 | 2 | 2006 |
| National Cancer Institute (NCI) | Government | 3 | 0 | 2 | 1998 |
| Indiana University | Academic/Hospital | 2 | 0 | 1 | 2006 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| University of Colorado, Denver | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Wisconsin | Academic/Hospital | 1 | 0 | 1 | 2008 |
8 organizations
Page 1 / 1